- Home
- AER vs MRNA Comparison
AER vs MRNA Comparison
Compare AER & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AER
- MRNA
- Stock Information
- Founded
- AER 1995
- MRNA 2010
- Country
- AER Ireland
- MRNA United States
- Employees
- AER N/A
- MRNA N/A
- Industry
- AER Diversified Commercial Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AER Consumer Discretionary
- MRNA Health Care
- Exchange
- AER Nasdaq
- MRNA Nasdaq
- Market Cap
- AER 17.7B
- MRNA 16.0B
- IPO Year
- AER 2006
- MRNA 2018
- Fundamental
- Price
- AER $103.29
- MRNA $27.22
- Analyst Decision
- AER Strong Buy
- MRNA Hold
- Analyst Count
- AER 9
- MRNA 20
- Target Price
- AER $116.44
- MRNA $54.47
- AVG Volume (30 Days)
- AER 2.3M
- MRNA 9.7M
- Earning Date
- AER 04-30-2025
- MRNA 05-01-2025
- Dividend Yield
- AER 1.05%
- MRNA N/A
- EPS Growth
- AER N/A
- MRNA N/A
- EPS
- AER 10.79
- MRNA N/A
- Revenue
- AER $7,996,644,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- AER $2.28
- MRNA N/A
- Revenue Next Year
- AER $2.76
- MRNA $22.07
- P/E Ratio
- AER $9.57
- MRNA N/A
- Revenue Growth
- AER 5.49
- MRNA N/A
- 52 Week Low
- AER $82.21
- MRNA $23.15
- 52 Week High
- AER $107.36
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- AER 59.08
- MRNA 47.01
- Support Level
- AER $93.28
- MRNA $26.33
- Resistance Level
- AER $98.86
- MRNA $27.88
- Average True Range (ATR)
- AER 4.14
- MRNA 1.84
- MACD
- AER 1.08
- MRNA 0.43
- Stochastic Oscillator
- AER 98.99
- MRNA 86.05
About AER AerCap Holdings N.V.
AerCap Holdings NV is an aircraft leasing company. Its major activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, United States, and Other countries.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.